Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study

Trial Profile

Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Fluorouracil (Primary) ; Imiquimod (Primary) ; Ingenol mebutate (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
    • 27 Oct 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2018.
    • 27 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top